| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 04/15/2009 | CN101406526A Compound scutellaria microemulsion formulation and preparation method thereof |
| 04/15/2009 | CN101406523A Chinese herbal medicine composition for treating coryza |
| 04/15/2009 | CN101406522A Use of pharmaceutical composition in preparing medicament for treating viral influenza |
| 04/15/2009 | CN101406493A Microsphere for injection of Cordyceps sinensis and preparation method thereof |
| 04/15/2009 | CN101406491A Oil-in-water Cordyceps sinensis emulsion and preparation technique |
| 04/15/2009 | CN101406474A Nalmefene injection and preparation method thereof |
| 04/15/2009 | CN100478030C SARS resisting medicine action target and its preventing and treating medicine |
| 04/15/2009 | CN100478016C Sarcandra solid dispersion and its preparing method |
| 04/15/2009 | CN100478004C Chinese medicinal composistion for treating common cold, its preparation method and quality control method |
| 04/15/2009 | CN100478003C Rabdosia extraction method |
| 04/15/2009 | CN100477990C Tanshinoue dropping pills and preparing method |
| 04/15/2009 | CN100477984C Infant Kechuanling Chinese medicine prepn for treating dyspneic cough and its prepn |
| 04/14/2009 | US7517996 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease |
| 04/14/2009 | US7517989 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/14/2009 | US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation |
| 04/14/2009 | US7517974 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders |
| 04/14/2009 | US7517879 Pyrrolidine derivatives as factor Xa inhibitors |
| 04/14/2009 | US7517875 Piperidine derivatives having CCR3 antagonism |
| 04/14/2009 | US7517861 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis |
| 04/14/2009 | US7517686 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 04/14/2009 | US7517661 Methods of screening for ligands for FPRL2 |
| 04/14/2009 | US7517658 Drug screening for human SNORF33 receptor agonist by contacting cells transfected with and expressing DNA encoding the human SNORF33 receptor, wherein cells prior to being transfected with the DNA do not express the human SNORF33 receptor; inflammation, infections, arthritis; autoimmune diseases |
| 04/14/2009 | CA2417050C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 04/14/2009 | CA2409841C Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| 04/14/2009 | CA2408934C Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| 04/14/2009 | CA2389111C Novel combination of loteprednol and .beta.2-adrenoceptor agonists |
| 04/14/2009 | CA2387844C Treatment of emphysema using rar selective retinoid antagonists |
| 04/14/2009 | CA2386190C Regulators of the hedgehog pathway, compositions and uses related thereto |
| 04/14/2009 | CA2359440C Phenylphenanthridines with pde-iv inhibiting activity |
| 04/14/2009 | CA2348871C Multiparticulate modified release composition |
| 04/14/2009 | CA2335900C Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| 04/14/2009 | CA2232378C Aerosol compositions |
| 04/09/2009 | WO2009045706A1 Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases |
| 04/09/2009 | WO2009045412A2 Methods of treatment using modified plasminogen activator inhibitor type-1 molecules |
| 04/09/2009 | WO2009044930A1 Pharmaceutical composition for inhibiting the accumulation of amyloid-β protein |
| 04/09/2009 | WO2009044899A1 Nucleic acid capable of regulating the proliferation of cell |
| 04/09/2009 | WO2009044788A1 Benzoxazinone derivative |
| 04/09/2009 | WO2009044147A1 Indolizine derivatives with crth2 receptor affinity for the treatment of inflammatory diseases |
| 04/09/2009 | WO2009044141A1 Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti -inflammatory and the use thereof for the treatment of respiratory disorders |
| 04/09/2009 | WO2009044134A1 Indolizine derivatives with crth2 receptor affinity for the treatment of inflammatory diseases |
| 04/09/2009 | WO2009043529A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043528A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043527A2 Therapeutic use of human growth hormone 1-43 |
| 04/09/2009 | WO2009043526A2 Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent |
| 04/09/2009 | WO2009043524A2 Use of a peptide as therapeutic agent |
| 04/09/2009 | WO2009043523A2 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 04/09/2009 | WO2009043522A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043521A2 Use of urocortin iii and urocortin i as therapeutic agents |
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043518A2 Use of a combination of cart peptides as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043480A2 Use of leptin (22-56 ) as a therapeutic agent |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043477A2 Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent |
| 04/09/2009 | WO2009043476A2 Neuromedin s as a therapeutic agent |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043468A2 Use of corticotropin-releasing factor as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043464A2 Astressin and beta- endorphin for use as therapeutic agents |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043452A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | WO2009043451A2 Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent |
| 04/09/2009 | WO2009043450A2 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 04/09/2009 | WO2009043449A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043448A2 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 04/09/2009 | WO2009043447A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043441A1 D-ala-gln-octadecyl ester as a therapeutic agent |
| 04/09/2009 | WO2009043440A2 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 04/09/2009 | WO2009043439A2 Use of retrocyclin- 1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043437A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/09/2009 | WO2009043436A2 Use of af12198 as a therapeutic agent |
| 04/09/2009 | WO2009043116A1 Methods and compositions for the treatment of phosphatase- related disorders |
| 04/09/2009 | WO2009043093A1 Hif inhibition |
| 04/09/2009 | WO2009005551A3 Transcription factor modulating compounds and methods of use thereof |
| 04/09/2009 | WO2008049000A3 Combination therapy for pulmonary arterial hypertension |
| 04/09/2009 | US20090093639 Prodrugs of carbamate inhibitors of IMPDH |
| 04/09/2009 | US20090093617 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 04/09/2009 | US20090093518 Piperidinyl-substituted isoquinolone derivatives |
| 04/09/2009 | US20090093503 Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 04/09/2009 | US20090093501 Heterocyclic antiviral compounds |
| 04/09/2009 | US20090093478 N-aroyl cyclic amines |
| 04/09/2009 | US20090093477 Tetrahydropyrrolopyrimidinediones and their use in therapy |
| 04/09/2009 | US20090093475 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals |
| 04/09/2009 | US20090093451 IL-8 Receptor Antagonists |